Lexicon Pharmaceuticals Inc. announced the results of a post-hoc analysis demonstrating that the addition of sotagliflozin to optimized insulin therapy reduces the risk of clinically important hypoglycemic events in adults with Type 1 Diabetes. These findings were presented at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ in Chicago, Illinois. The analysis evaluated the effect of kidney function on hypoglycemia risk, using pooled data from inTandem 1 and inTandem 2 Phase 3 clinical trials. The results indicated that sotagliflozin reduces hypoglycemia events, particularly in patients with blood glucose levels ≤55 mg/dL, across various kidney function subgroups without increasing the risk of severe hypoglycemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.